AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27763802 — intervention group
Group type: EXPERIMENTAL
Intervention: BMO‐30 (extract from Schisandra chinensis)
Number of subjects: 36
Study 27763802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 25030779 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 11
Study 25030779 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 11
Study 22850440 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic mode
Number of subjects: 135
Study 22850440 — intervention group
Group type: COMPARATOR
Intervention: Usual mode
Number of subjects: 135
Study 20390482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk-reduction intervention delivered in four sessions
Number of subjects: 270
Study 20390482 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 270
Study 18534218 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose indomethacin (0.2 or 0.5 mg/kg/d)
Number of subjects: 105
Study 18534218 — intervention group
Group type: COMPARATOR
Intervention: Low-dose indomethacin (0.1 mg/kg/d)
Number of subjects: 105
Study 15755044 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 129
Study 15755044 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (leuprolide acetate)
Number of subjects: 129
Study 14557467 — intervention group
Group type: EXPERIMENTAL
Intervention: oral glucose, iv octreotide
Number of subjects: 15
Study 14557467 — intervention group
Group type: COMPARATOR
Intervention: oral glucose, iv saline
Number of subjects: 15
Study 14557467 — intervention group
Group type: EXPERIMENTAL
Intervention: iv octreotide alone
Number of subjects: 15
Study 11050700 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release chitosan formulation of pentoxifylline
Number of subjects: 12
Study 11050700 — intervention group
Group type: COMPARATOR
Intervention: Commercial formulation of pentoxifylline
Number of subjects: 12
Study 8805732 — intervention group
Group type: EXPERIMENTAL
Intervention: White petrolatum
Number of subjects: 922
Study 8805732 — intervention group
Group type: COMPARATOR
Intervention: Bacitracin
Number of subjects: 922
Study 1515255 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-2b interferon maintenance after double hemi-body irradiation
Number of subjects: 59
Study 1515255 — intervention group
Group type: COMPARATOR
Intervention: Single hemi-body irradiation alone
Number of subjects: 59
Study 1515255 — intervention group
Group type: EXPERIMENTAL
Intervention: Double hemi-body irradiation with interferon
Number of subjects: 59
Study 1515255 — intervention group
Group type: COMPARATOR
Intervention: Double hemi-body irradiation without interferon
Number of subjects: 59
Study 6139745 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids and sulfasalazine (group A)
Number of subjects: 26
Study 6139745 — intervention group
Group type: EXPERIMENTAL
Intervention: Elementary diet and sulfasalazine (group B)
Number of subjects: 26
Study 6139745 — intervention group
Group type: EXPERIMENTAL
Intervention: Elementary diet with steroids and sulfasalazine (group C)
Number of subjects: 26
Study 30562676 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Health CoOp Plus (WHC+)
Number of subjects: 641
Study 30562676 — intervention group
Group type: COMPARATOR
Intervention: HIV counseling and testing (HCT)
Number of subjects: 641
Study 29874528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg daily)
Number of subjects: 100
Study 29874528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26707678 — intervention group
Group type: EXPERIMENTAL
Intervention: Stride length increased by +25%
Number of subjects: 19
Study 26707678 — intervention group
Group type: EXPERIMENTAL
Intervention: Stride length decreased by -25%
Number of subjects: 19
Study 26707678 — intervention group
Group type: COMPARATOR
Intervention: Control (desired stride length)
Number of subjects: 19
Study 25169211 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive health check (Intervention group)
Number of subjects: 10505
Study 25169211 — intervention group
Group type: COMPARATOR
Intervention: Routine access to healthcare until a delayed intervention (Comparison group)
Number of subjects: 10505
Study 22353644 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline (1mg)
Number of subjects: 727
Study 22353644 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (40 IU)
Number of subjects: 727
Study 20705796 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) for diagnosis of OSA
Number of subjects: 165
Study 17548410 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-directed advice
Number of subjects: 259
Study 17548410 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-directed exercise
Number of subjects: 259
Study 17548410 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and advice
Number of subjects: 259
Study 10710049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) pantoprazole (40 mg and 20 mg)
Number of subjects: 65
Study 10710049 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (p.o.) pantoprazole (40 mg and 20 mg)
Number of subjects: 65
Study 10710049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v.)
Number of subjects: 65
Study 10436615 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg
Number of subjects: 145
Study 10436615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 1485530 — intervention group
Group type: EXPERIMENTAL
Intervention: Raclopride 2‐8 mg twice daily
Number of subjects: 91
Study 1485530 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 5‐20 mg twice daily
Number of subjects: 91
Study 3545629 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque, 350 mg I/ml
Number of subjects: 38
Study 3545629 — intervention group
Group type: COMPARATOR
Intervention: Urografin, 370 mg I/ml
Number of subjects: 38
Study 30954481 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment of cases (women with stillbirth)
Number of subjects: 1269
Study 30954481 — intervention group
Group type: COMPARATOR
Intervention: Recruitment of controls (matched for region and gestation)
Number of subjects: 1269
Study 30954481 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-participation reasons
Number of subjects: 1269
Study 30954481 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant feedback
Number of subjects: 1269
Study 30954481 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback themes
Number of subjects: 1269
Study 28507219 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab (30 mg/m2 of body surface area; maximum: 50 mg/dose) every 4 weeks with weekly methotrexate
Number of subjects: 173
Study 28507219 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab
Number of subjects: 173
Study 28507219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 27370059 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 68
Study 27370059 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 68
Study 27370059 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 68
Study 27370059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 24476416 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETA)
Number of subjects: 112
Study 24476416 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 112
Study 22710953 — intervention group
Group type: EXPERIMENTAL
Intervention: C-LETZ
Number of subjects: 98
Study 22710953 — intervention group
Group type: COMPARATOR
Intervention: LLETZ
Number of subjects: 98
Study 20465033 — intervention group
Group type: EXPERIMENTAL
Intervention: Khat chewing
Number of subjects: 17
Study 20465033 — intervention group
Group type: COMPARATOR
Intervention: Non-chewers
Number of subjects: 17
Study 18322991 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone
Number of subjects: 25
Study 18322991 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg etanercept
Number of subjects: 25
Study 15978098 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU bolus followed by 0.5 x 10(6) KIU h(‐1) for 3 h)
Number of subjects: 0
Study 15978098 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA) (10 g over 30 min followed by 5 g over 3 h)
Number of subjects: 0
Study 15978098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12679467 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (r‐hFSH) at doses of 0, 37.5, 75, or 150 IU
Number of subjects: 23
Study 12679467 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (r‐hFSH) at doses of 37.5 IU and 75 IU
Number of subjects: 23
Study 12679467 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (r‐hFSH)
Number of subjects: 23
Study 10568855 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 92
Study 10568855 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 92
Study 8707193 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula with starch (25 infants)
Number of subjects: 46
Study 8707193 — intervention group
Group type: COMPARATOR
Intervention: Cow milk-based formula (21 infants)
Number of subjects: 46
Study 1884058 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 1 mg given daily for one week before and three weeks after surgery
Number of subjects: 148
Study 1884058 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 148
Study 31523919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment (power 12 W, time on 3 ms, PPI 5), two sessions four weeks apart
Number of subjects: 60
Study 31523919 — intervention group
Group type: COMPARATOR
Intervention: Topical keratolytic (10% urea)
Number of subjects: 60
Study 31523919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment
Number of subjects: 60
Study 30500610 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile sex workers (2016)
Number of subjects: 2591
Study 30500610 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile sex workers (2013)
Number of subjects: 2591
Study 30500610 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile sex workers
Number of subjects: 2591
Study 27965261 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ-cultured corneas with endothelial cell density (ECD) measured at day 5 after PK
Number of subjects: 90
Study 25892544 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure intervention (two-session coping skills intervention)
Number of subjects: 699
Study 25892544 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 699
Study 23859414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna treatment (30 minutes, 3 days per week for 6 weeks)
Number of subjects: 26
Study 23859414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna treatment
Number of subjects: 26
Study 23859414 — intervention group
Group type: COMPARATOR
Intervention: Control (education and normal life)
Number of subjects: 26
Study 21233778 — intervention group
Group type: EXPERIMENTAL
Intervention: HEALTHY intervention (improved school food environment, physical activity and eating educational sessions, social marketing, revised physical education curriculum)
Number of subjects: 42
Study 21233778 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard school environment)
Number of subjects: 42
Study 21233778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (HEALTHY intervention)
Number of subjects: 42
Study 19254073 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 0
Study 19254073 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17654308 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/d)
Number of subjects: 10
Study 17654308 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg/d)
Number of subjects: 10
Study 17654308 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 10
Study 17654308 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and Rofecoxib
Number of subjects: 10
Study 16201847 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole flaxseed (FB)
Number of subjects: 0
Study 12115946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (CP; n = 12)
Number of subjects: 23
Study 12115946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL; n = 11)
Number of subjects: 23
Study 9927358 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 4 weeks
Number of subjects: 34
Study 9927358 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 4 weeks
Number of subjects: 34
Study 7473117 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisc (n = 32)
Number of subjects: 61
Study 7473117 — intervention group
Group type: COMPARATOR
Intervention: Healon (n = 29)
Number of subjects: 61
Study 7473117 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisc and Healon
Number of subjects: 61
Study 2299367 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lung biopsy (OLB) within 8 hours of presentation
Number of subjects: 24
Study 2299367 — intervention group
Group type: COMPARATOR
Intervention: Empiric antimicrobial therapy (ET) with trimethoprim‐sulfamethoxazole (TMP‐SMX) and erythromycin for a minimum of 4 days
Number of subjects: 24
Study 2299367 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined randomized and non-randomized groups
Number of subjects: 24
Study 2299367 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lung biopsy (OLB)
Number of subjects: 24
Study 2299367 — intervention group
Group type: COMPARATOR
Intervention: Empiric antimicrobial therapy (ET)
Number of subjects: 24
Study 2299367 — intervention group
Group type: COMPARATOR
Intervention: Complication rate comparison between patients receiving only empiric antibiotics and all patients having an OLB
Number of subjects: 24
Study 7014999 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25-0.5% timolol maleate
Number of subjects: 40
Study 7014999 — intervention group
Group type: COMPARATOR
Intervention: 0.1% epinephrine hydrochloride
Number of subjects: 40
Study 7014999 — intervention group
Group type: COMPARATOR
Intervention: 1% epinephrine
Number of subjects: 40
Study 30052090 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% solution once daily for 48 weeks plus 1064 nm Nd: YAG laser (6 treatments every 4 weeks)
Number of subjects: 30
Study 30052090 — intervention group
Group type: COMPARATOR
Intervention: Efinaconazole 10% solution once daily for 48 weeks
Number of subjects: 30
Study 27417502 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive e-Health tool
Number of subjects: 176
Study 27417502 — intervention group
Group type: EXPERIMENTAL
Intervention: Print materials
Number of subjects: 176
Study 27417502 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 176
Study 26114410 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 100
Study 26114410 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A (control)
Number of subjects: 100
Study 24046309 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oseltamivir twice daily for 5 days
Number of subjects: 155
Study 24046309 — intervention group
Group type: COMPARATOR
Intervention: 75 mg oseltamivir twice daily for 5 days
Number of subjects: 155
Study 24046309 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oseltamivir (subanalysis for influenza B)
Number of subjects: 155
Study 24046309 — intervention group
Group type: COMPARATOR
Intervention: 75 mg oseltamivir (subanalysis for influenza B)
Number of subjects: 155
Study 21829903 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group intervention focused on nutrition counseling, lifestyle, physical activity and self-esteem
Number of subjects: 1071
Study 19788487 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG) tube
Number of subjects: 20
Study 19788487 — intervention group
Group type: COMPARATOR
Intervention: Non-PEG patients
Number of subjects: 20
Study 17086018 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 35
Study 17086018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15381506 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy of making hip protectors available free of charge to residents, supported by a nurse facilitator over a 72-week period.
Number of subjects: 4137
Study 15381506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hip protectors provided).
Number of subjects: 4137
Study 15381506 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial acceptance of hip protectors was 37.2% (508/1,366) with adherence falling to 19.9% (272/1,366) at 72 weeks.
Number of subjects: 4137
Study 11700183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (180, 360, and 540 microg doses)
Number of subjects: 114
Study 11700183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 11700183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (all doses)
Number of subjects: 114
Study 11700183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (360 microg)
Number of subjects: 114
Study 9812793 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator headgear combination appliance
Number of subjects: 52
Study 9812793 — intervention group
Group type: COMPARATOR
Intervention: Untreated children (control group)
Number of subjects: 52
Study 8273795 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g amoxicillin tid intravenously (n = 15)
Number of subjects: 31
Study 8273795 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg amoxicillin six times daily orally (n = 16)
Number of subjects: 31
Study 3111339 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanone (PDS)
Number of subjects: 284
Study 3111339 — intervention group
Group type: COMPARATOR
Intervention: Prolene
Number of subjects: 284
Study 29513931 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 557 210 mg
Number of subjects: 20
Study 29513931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27271554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (n = 23)
Number of subjects: 41
Study 27271554 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (n = 18)
Number of subjects: 41
Study 24767892 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 387
Study 24767892 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived helpfulness ratings
Number of subjects: 387
Study 24094085 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention with 5 interactive booklets about adolescent substance use and risky sexual behavior
Number of subjects: 340
Study 20803419 — intervention group
Group type: EXPERIMENTAL
Intervention: HD+ colonoscopy with I-Scan functionality
Number of subjects: 220
Study 20803419 — intervention group
Group type: COMPARATOR
Intervention: Standard video colonoscopy
Number of subjects: 220
Study 17440525 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic acid, low-trans semiliquid fat
Number of subjects: 44
Study 15946144 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-10)
Number of subjects: 120
Study 11854877 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS)
Number of subjects: 72
Study 11854877 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 72
Study 10078677 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg midazolam in 15 mg/kg acetaminophen orally
Number of subjects: 86
Study 10078677 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/kg acetaminophen orally (placebo)
Number of subjects: 86
Study 8652038 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium (10 mg for < 55 kg; 20 mg for > 55 kg)
Number of subjects: 108
Study 8652038 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordiazepam (1 gtt/kg; 5 mg = 24 gtt)
Number of subjects: 108
Study 8652038 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium (evening and morning)
Number of subjects: 108
Study 8652038 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium (evening) and Nordiazepam (morning)
Number of subjects: 108
Study 1977531 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 780
Study 1977531 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 780
Study 6444862 — intervention group
Group type: EXPERIMENTAL
Intervention: Actinac (lotion with chloramphenicol)
Number of subjects: 37
Study 6444862 — intervention group
Group type: COMPARATOR
Intervention: Formulation without chloramphenicol
Number of subjects: 37
Study 31801673 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial high-risk (FHR) group
Number of subjects: 15
Study 31801673 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 15
Study 31780347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 592
Study 31780347 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 592
Study 29499997 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat
Number of subjects: 418
Study 29499997 — intervention group
Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 418
Study 27209439 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (daily capsule containing Lactobacillus acidophilus, L. casei, and Bifidobacterium bifidum for 6 weeks)
Number of subjects: 60
Study 27209439 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 60
Study 27209439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24301228 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleph inactivated split influenza vaccine
Number of subjects: 3308